Clinical trial · Interventional
Effect of Shock Wave In Reducing Chemotherapy- Induced Peripheral Neuropathy In Adult and Pediatric Tumors Patients
Effect of Shock Wave In Reducing Chemotherapy- Induced Peripheral Neuropathy In Adult and Pediatric Tumors Patients:A Randomized Controlled Trail
NCT05111730CI-TRIAL-00054941unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to assess the efficacy of shock wave in reducing Chemotherapy- Induced Peripheral Neuropathy in adult and pediatric tumors patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The Shock wave Therapy. | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- The shockwave Group
- description
- Group (A) study group received medical care and standard chemotherapy and shock wave, three times / week for three successful months.
- interventionNames
- Device: The Shock wave Therapy.
- type
- NO_INTERVENTION
- label
- the traditional treatment group
- description
- group (B) control group received medical care and standard chemotherapy only.
Primary outcomes (6)
- measure
- Malondialdehyde (MDA) as oxidative stress marker
- timeFrame
- Malondialdehyde (MDA) level was assessed at day 0.
- description
- Malondialdehyde level in blood will be measured
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Their age will ranging from eight to forty years. * All cases participated in this study will from both sexes. * All cases receiving chemotherapy as primary treatment, postoperative surgical removal of tumors or with conjunction with radiotherapy * All cases have polyneuropathy caused by chemotherapy. Exclusion Criteria: * Patient with osteoporosis. * Patient with DVT. * Patient have a Pacemaker fitted * Uncooperative patients
References
Publications (0)
Data not yet available
No reference posted for this study.